What you need to know about the cholesterol trial that could swing billions

Is a small company poised to shake up the multibillion-dollar market for cardiovascular drugs, or is it about to descend into irrelevance?

That’s the question hanging over Esperion Therapeutics and its experimental cholesterol-cutting therapy. The drug is being developed as an option for patients who can’t get what they need from cheap, generic statins but who also don’t require pricey injectable medicines called PCSK9 inhibitors, which can cost more than $10,000 a year.

But the plan only works if Esperion can convince the Food and Drug Administration that its treatment is safe for long-term use.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In